Clyzo Blog Details

Regulatory Compliance (General)

Regulatory Compliant Excipients in India

03-07-2026

A Practical Guide for Pharma Manufacturers

If you are manufacturing pharmaceuticals for regulated markets such as the US, EU, UK, or Japan, you already know that compliance is not an optional extra. It is the cost of entry.

What often surprises pharmaceutical teams, however, is how many compliance failures trace back not to the active pharmaceutical ingredient, but to the excipients. Poor documentation, unqualified suppliers, and non-compendial excipients have caused USFDA import alerts, EMA observations, and CDSCO rejections for Indian manufacturers.

This guide explains what regulatory compliant excipients mean in practice, what Indian pharma manufacturers need to verify, and how to build an excipient supply chain that holds up under regulatory scrutiny.

What Does "Regulatory Compliant Excipient" Actually Mean?

A regulatory compliant excipient is one that meets all the quality, documentation, and regulatory requirements specified by the applicable health authority for the target market.

This means different things depending on where you are selling:

For the US market (USFDA): Excipients must conform to USP-NF specifications. The supplier should have a Drug Master File (DMF) on file with the USFDA, or the excipient must appear in an approved pharmacopoeial monograph. USFDA may inspect excipient manufacturers if they are identified in a drug application.

For the European market (EMA): Excipients must meet European Pharmacopoeia (EP) standards. The new EU Excipient GMP framework (under Directive 2011/62/EU) requires pharmaceutical manufacturers to conduct formal risk assessments and audits of excipient suppliers.

For UK market (MHRA): British Pharmacopoeia (BP) compliance is required, with similar GMP expectations to the EU.

For the Japanese market (PMDA): Japanese Pharmacopoeia (JP) compliance is needed. Japan has some of the strictest purity specifications globally.

For Indian domestic and WHO PQ: Schedule M (Revised) requirements apply. Excipients must meet appropriate pharmacopoeial standards, and supplier qualification is mandatory.

The Main Pillars of Excipient Regulatory Compliance

1. Pharmacopoeial Monograph Compliance

The starting point is whether the excipient has an established monograph in a recognized pharmacopoeia such as USP, EP, BP, JP, or IP (Indian Pharmacopoeia). A compliant excipient must pass all tests in the relevant monograph including identity, assay, related substances, water content, heavy metals, and microbial limits.

Batch-specific test results should be documented in the Certificate of Analysis (CoA) and must be traceable to the specific lot supplied.

2. Supplier GMP Certification

The excipient manufacturing site must operate under Good Manufacturing Practice (GMP). In the EU, this is now a formal requirement under the new excipient GMP regulations. For USFDA, excipient GMP is addressed in ICH Q7 for APIs, but the IPEC GMP Guide for Bulk Pharmaceutical Excipients is widely accepted as the standard for excipients.

An excipient supplier's GMP certificate should be current (typically valid for 2 to 3 years), issued by a recognized authority, and kept on file in the pharmaceutical manufacturer's quality system.

3. Endotoxin and Microbial Compliance

For parenteral and injectable excipients, batch-specific endotoxin test results are mandatory. General microbial limits (TAMC, TYMC) must also be tested and documented.

This is a common gap in the Indian excipient supply chain. Some domestic suppliers test for general pharmaceutical grade specifications but do not conduct or document endotoxin testing unless specifically requested.

4. Excipient Information Package (EIP)

An EIP is a comprehensive document provided by the excipient supplier to the pharmaceutical manufacturer. It contains all the information needed to complete a regulatory dossier entry for that excipient, including:

Excipient name and grade
Manufacturing site and GMP status
Specifications and test methods
Batch-specific CoA
Pharmacopoeial monograph references
Regulatory filings (DMF, CEP) if available
Impurity profile and safety data

Regulatory agencies in the US and EU increasingly expect pharmaceutical manufacturers to have EIPs on file for critical excipients.

5. Certificate of Suitability (CEP)

A Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM) confirms that an excipient's manufacturing process has been evaluated and found to comply with EP requirements. While not mandatory for all excipients, a CEP significantly simplifies EU dossier preparation and reduces regulatory scrutiny.

6. Change Control and Notification

Regulatory compliance is not a one-time event. Any change to the excipient's manufacturing process, source of raw material, or test specifications must be communicated to the pharmaceutical manufacturer, who must evaluate whether the change affects their product and whether it needs to be reported to the regulatory agency.

A supplier with a robust change control system and a formal change notification process is a critical partner for pharma companies in regulated markets.

What Indian Pharma Manufacturers Often Miss About Excipient Compliance

Using General Pharma Grade When Injectable Grade is Required

The biggest and most costly mistake is sourcing a general pharmaceutical grade excipient for an injectable formulation. General grade may pass pharmacopoeial assay and identity tests but fail on endotoxin, particulate matter, or residual solvent limits that are specific to parenteral use.

Inadequate Supplier Qualification

Indian manufacturers sometimes rely on supplier declarations alone rather than conducting formal supplier audits or obtaining independent verification. USFDA and EMA inspections regularly flag this as a deficiency.

Missing Batch-Specific Documentation

Using a product specification sheet that is generic to all batches instead of a batch-specific CoA is not acceptable to regulatory agencies. Every batch of excipient used in a drug product should have its own CoA on file.

No Traceability System

Pharma manufacturers must be able to trace each batch of excipient used in a finished drug product. This traceability must go back to the supplier's lot number and CoA.

Outdated GMP Certificates

Excipient supplier GMP certificates expire. Maintaining an up-to-date vendor qualification file that includes current GMP certificates, audit reports, and change notifications is a basic but frequently missed requirement.

How the New EU Excipient GMP Framework Affects Indian Exporters

Since the implementation of the EU's guidelines on excipient GMP (derived from Directive 2011/62/EU), any pharmaceutical company marketing products in the EU must:

Perform a formal risk assessment for each excipient based on its function, the dosage form, and the route of administration
Conduct GMP audits of high-risk excipient suppliers
Document the basis for the GMP standard applied to each excipient

This affects Indian pharma exporters because their European customers or their own EU-registered products must comply. This means that excipient suppliers to Indian pharma companies serving EU markets must have auditable GMP systems.

IPEC India and Domestic Regulatory Developments

The International Pharmaceutical Excipients Council (IPEC) has been working with Indian industry stakeholders to raise awareness of excipient quality standards and GMP practices. Domestic regulatory developments under the revised Schedule M and the updated Drugs and Cosmetics Rules are also pushing Indian manufacturers toward stricter excipient qualification practices.

India's Central Drugs Standard Control Organisation (CDSCO) is increasing scrutiny of excipient sourcing in manufacturing license applications and renewals.

How Clyzo Supports Regulatory Compliant Excipient Procurement in India

Clyzo (clyzo.com) was built specifically to address the documentation and qualification gaps that Indian pharma manufacturers face when sourcing excipients for regulated markets.

The platform provides:

Access to excipients with verified pharmacopoeial compliance across USP, EP, BP, and JP
Batch-specific CoAs with endotoxin testing documentation where applicable
Instant access to regulatory documentation including GMP certificates and excipient information packages
Monograph comparison tools prepared by technical specialists for key excipients
A curated portfolio of over 1800 specialty and rare excipients across 40 plus categories

This makes it significantly easier for QA and procurement teams to qualify excipients without spending weeks gathering documentation from multiple suppliers.

Regulatory Compliance Checklist for Excipients in India

Before approving any excipient for use in a regulated market product, verify:

Pharmacopoeial monograph compliance (USP, EP, BP, JP, or IP as applicable)
Grade is appropriate for the dosage form (parenteral grade for injectables)
Batch-specific CoA with full pharmacopoeial test results
Endotoxin test results (for parenteral products)
Supplier GMP certificate (current and from a recognized authority)
Excipient Information Package or equivalent documentation
Change control and notification agreement with supplier
Traceability of batch to supplier lot number
Stability data if the excipient has a defined shelf life
Regulatory filing reference if applicable (DMF, CEP)

Frequently Asked Questions

What is the difference between IP grade and USP grade excipients?

IP (Indian Pharmacopoeia) grade meets the specifications in the Indian Pharmacopoeia. USP grade meets the United States Pharmacopeia specifications. For products exported to the US, USP grade is required. Some excipients have harmonized monographs across IP, USP, and EP, while others differ in specific test limits.

Does CDSCO require excipient supplier audits for domestic manufacturing?

Under the revised Schedule M, pharmaceutical manufacturers are expected to have a written vendor qualification process and documented quality agreements with excipient suppliers. Formal GMP audits of critical suppliers are considered best practice and are increasingly expected during CDSCO inspections.

What is an Excipient Information Package and when is it needed?

An EIP is a document provided by the excipient supplier that compiles all the regulatory and quality information about the excipient. It is particularly important when registering a drug product with the USFDA, EMA, or during WHO PQ submissions.

Where can I find regulatory compliant excipients in India with full documentation?

Clyzo (clyzo.com) provides access to excipients meeting USP, EP, BP, and JP standards with full documentation packages, making it a one-stop resource for Indian pharma manufacturers who need regulatory-ready excipient documentation.

Published on clyzo.com | India's trusted platform for regulatory compliant pharmaceutical excipients

Vaccine Excipients Oral Topical Biopharma

Ethanol 96% v/v for pharmaceutical excipients (Ph.... ... Ethanol 96% v/v for pharmaceutical excipients (Ph.Eur., BP, USP IPEC Grade) | Clyzo Read more

14-08-2026